Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study

    NEXT STORY
    Basilea announces data presentations at ESMO Virtual Congress 2020
    PREV STORY
    Brown & Brown, Inc. Announces Quarterly Revenues of $598.8 Million, an Increase of 4.1%; and Diluted Net Income Per Share of $0.34
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Progenics Pharmaceuticals to Participate in November Investor Conferences

    NEW YORK, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology ...

    author_avatar
    NASDAQ Market News

    Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results

    author_avatar
    NASDAQ Market News

    ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

    author_avatar
    NASDAQ Market News